These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25670523)

  • 21. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
    Cicali B; Lingineni K; Cristofoletti R; Wendl T; Hoechel J; Wiesinger H; Chaturvedula A; Vozmediano V; Schmidt S
    CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):48-58. PubMed ID: 33217171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
    Chiang M; Sychterz C; Perera V; Merali S; Palmisano M; Templeton IE; Gaohua L
    Clin Pharmacol Ther; 2023 Oct; 114(4):922-932. PubMed ID: 37467157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
    Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
    Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
    J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.
    Okudaira N; Burt H; Mitra A
    CPT Pharmacometrics Syst Pharmacol; 2024 Aug; 13(8):1366-1379. PubMed ID: 38807307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4.
    Templeton I; Ravenstijn P; Sensenhauser C; Snoeys J
    Biopharm Drug Dispos; 2016 Jan; 37(1):15-27. PubMed ID: 26356245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects.
    Aslanis V; Umehara K; Huth F; Ouatas T; Bharathy S; Butler AA; Zhou W; Gadbaw B
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):749-757. PubMed ID: 31324935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lurasidone drug-drug interaction studies: a comprehensive review.
    Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
    Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
    Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
    J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4.
    Liu T; Gobburu JVS
    J Pharm Sci; 2018 Mar; 107(3):942-948. PubMed ID: 29102550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
    Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
    Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically based pharmacokinetic modeling of ponatinib to describe drug-drug interactions in patients with cancer.
    Morita TO; Hanada K
    Cancer Chemother Pharmacol; 2022 Oct; 90(4):315-323. PubMed ID: 35997844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
    Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
    Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
    Ling SY; Huizinga RB; Mayo PR; Larouche R; Freitag DG; Aspeslet LJ; Foster RT
    Br J Clin Pharmacol; 2014 Jun; 77(6):1039-50. PubMed ID: 24330024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.